Tri-Heal Max (TB-500 + BPC-157 + KPV)
Educational information only — not medical advice. Many listed compounds are not FDA-approved for human use. Consult a licensed clinician before starting, changing, or stopping any protocol.
Overview
Tri-Heal Max is a combination research product that packages three separate peptides into a single pre-mixed vial: TB-500, BPC-157, and KPV. It is marketed as an advanced, high-dose blend aimed at tissue repair and inflammation, drawing on the individual reputations of its three components rather than on evidence for the combination itself.
Each component has been studied separately, mostly in animal or laboratory models. TB-500 is a synthetic fragment of thymosin beta-4 and BPC-157 is a synthetic gastric pentadecapeptide; both are commonly discussed in the context of recovery and connective-tissue healing. KPV is a short tripeptide derived from the C-terminal end of alpha-melanocyte-stimulating hormone (alpha-MSH) and is studied primarily for anti-inflammatory activity.
The blend has not been evaluated in controlled human trials, and none of the three peptides is approved by a major regulator for therapeutic use. It is sold for research purposes only.
How it works
The rationale behind the blend is that its components act on different but complementary pathways. In preclinical work, TB-500 (via thymosin beta-4) is reported to promote cell migration and angiogenesis by modulating the actin cytoskeleton, while BPC-157 has been studied for effects on new blood-vessel formation and growth-factor pathways involved in tendon and ligament repair. KPV is studied for its apparent ability to dampen inflammatory signaling, including NF-kB-related pathways downstream of alpha-MSH.
Whether these mechanisms combine additively or synergistically in a single formulation has not been established. The interactions, absorption, and net effect of the three peptides together in humans are not characterized.
Reported benefits
- Support for recovery from tendon, ligament, and muscle injury (from animal data on TB-500 and BPC-157)
- Reduced local inflammation (KPV is studied for anti-inflammatory activity)
- Improved tissue repair and connective-tissue organization in preclinical models
These are reported and studied effects for the individual components, not guaranteed outcomes for the blend, which has not been clinically tested.
Considerations & side effects
Because there are no controlled human trials of this combination — or of the individual peptides at these research doses — the long-term safety profile is not well characterized. Reported side effects for the component peptides are generally described as mild and include injection-site irritation, lightheadedness, and nausea, but combining three peptides in one vial adds uncertainty about interactions and total exposure.
Product purity and actual content vary widely in the research-chemical market, and multi-peptide pre-mixed vials can be harder to verify than single compounds. This information is educational only and is not a substitute for evaluation and treatment by a qualified clinician.
Frequently asked
What is Tri-Heal Max?
A pre-mixed research blend that combines three peptides in a single vial: TB-500 (a fragment of thymosin beta-4), BPC-157 (a synthetic gastric pentadecapeptide), and KPV (a tripeptide derived from alpha-MSH). It is positioned as a high-dose tissue-repair and anti-inflammatory combination.
Are these peptides FDA-approved?
No. None of the three component peptides — TB-500, BPC-157, or KPV — is approved by the FDA or any major regulator for human therapeutic use. They are sold for research purposes only.
Why combine three peptides in one vial?
The blend pairs compounds studied for complementary roles: TB-500 and BPC-157 are both associated with tissue repair in animal models, while KPV is studied mainly for anti-inflammatory activity. Combining them in one vial is a convenience-driven formulation choice, not an approved or clinically validated protocol.
Is there human clinical evidence for this combination?
No controlled human trials have evaluated this specific three-peptide blend. Most evidence for each individual component comes from preclinical (animal or cell) studies, and the combination itself has not been formally studied.
How is it typically administered?
As a reconstituted injectable, usually subcutaneously. Because it is a research product, purity and actual content are not independently guaranteed.
References
- Ho CH, et al. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. ↗
- Gwyer D, et al. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. ↗
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. ↗
- Getting SJ, et al. Dissection of the anti-inflammatory effect of the core and C-terminal (KPV) alpha-melanocyte-stimulating hormone peptides. ↗
Related compounds
Pre-mixed blend of BPC-157 and TB-500, the most popular healing combination. Sold as a single combined vial from compounding pharmacies for injury recovery and tissue repair.
Four-peptide regenerative blend combining GHK-Cu (50mg), KPV (10mg), BPC-157 (10mg), and TB-500 (10mg). Advanced healing and anti-inflammatory protocol. Sold as a single 80mg pre-mixed vial.
An 11-amino-acid peptide modeled on the tissue-protective domain of erythropoietin that selectively activates the innate repair receptor, driving tissue protection and anti-inflammatory effects without raising red blood cell count. Studied for small-fiber and diabetic neuropathy.